natgillin/translations-raw huggingface dataset:
Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil plastic tubes: EU/1/13/904/004
Višeslojne plastične tube od polietilena (PE)/kopolimera/aluminija (Al)/kopolimera/polietilena (PE): EU/1/13/904/004
Polyethylene bottle
Polietilenska bočica
Polyethylene bottle containing 10 ml, 15 ml or 30 ml with a polyethylene dropper and a tamper proof child resistant closure.
Polietilenska bočica od 10 ml, 15 ml ili 30 ml, s polietilenskom kapaljkom i sigurnosnim zatvaračem za zaštitu od djece.
Polyethylene bottle containing 10 ml, 32 ml, 100 ml or 180 ml with a polyethylene dropper and a tamper proof child resistant closure.
Polietilenska bočica koja sadrži 10 ml, 32 ml, 100 ml ili 180 ml s polietilenskom kapaljkom i sigurnosnim zatvaračem za zaštitu od djece.
Polyethylene bottle containing 15 ml or 30 ml with a polyethylene dropper and a tamper proof child resistant closure.
Polietilenska bočica koja sadrži 15 ml ili 30 ml s polietilenskom kapaljkom i sigurnosnim zatvaračem za zaštitu od djece.
Polyethylene bottle of 20 ml (10 doses), 100 ml (50 doses) or 250 ml (125 doses) sealed with a rubber closure and secured with an aluminium cap.
Polietilenska bočica od 20 ml (10 doza), 100 ml (50 doza) ili 250 ml (125 doza) zapečaćena gumenim zatvaračem i osigurana aluminijskim zatvaračem.
Polyethylene bottle with a chlorobutyl elastomer closure and aluminium cap.
Polietilenska bočica sa čepom od klorbutil elastomera i zapečaćena aluminijskom kapicom.
Polyethylene bottle with a chlorobutyl elastomer closure and aluminium cap.
Polietilenska bočica sa čepom od klorbutil elastomera i zapečaćene aluminijskom kapicom.
Polyethylene bottles with a chlorobutyl elastomer closure and aluminium cap.
Polietilenske bočice sa čepom od klorbutil elastomera i zapečaćena aluminijskom kapicom.
Polyethylene glycol 3350
polietilenglikol 3350
polyethylene perfusion tubings with an inner diameter of 1 mm and a length of 150 cm polycarbonate infusion valves / Y connections polyurethane, polyurethane silicon coated catheters
polietilenskim perfuzijskim cijevima s unutrašnjim promjerom od 1 mm i dužinom od 150 cm polikarbonantnim infuzijskim ventilima/Y spoj poliuretanom, poliuretanskim kateterima obloženim silikonom
Polyethylene tablet container with CRC polypropylene cap.
Polietilenski spremnik za tablete s polipropilenskim sigurnosnim zatvaračem za djecu.
Polyethylene terephthalate bottle containing 10, 32, 100, 2 x 100 or 200 ml with two polyethylene/polypropylene measuring syringes.
Polietilen tereftalata bočica sadrži 10, 32, 100, 2 x 100 ili 200 ml i dvije polietilenske/polipropilenske mjerne štrcaljke.
Polyethylene terephthalate bottle containing 15 or 30 ml with two polyethylene/polypropylene measuring syringes.
Polietilen tereftalata bočica sadrži 15 ili 30 ml i dvije polietilenske/polipropilenske mjerne štrcaljke.
Polyethylene terephthalate bottle, HDPE/LDPE cap, polypropylene / polyethylene measuring syringe
Polietilenskim tereftalata bočicama s navojnim i HDPE/LDPE čepovima, polietilenske/polipropilenske mjerne štrcaljke
Polyethylene terephthalate bottle, HDPE/LDPE cap, polypropylene / polyethylene measuring syringe.
Polietilenskim tereftalata bočicama s navojnim i HDPE/LDPE čepovima, polietilenske/polipropilenske mjerne štrcaljke,
Polyethylene/aluminium/polyethylene terephthalate foil sachet.
Vrećica od polietilen/aluminij/polietilen tereftalatne folije.
Polyglucose-sorbitol carboxymethylether (PSC) Mannitol
poliglukoza-sorbitol karboksimetileter (PSC) manitol
polymyalgia rheumatica
reumatska polimialgija
polymyalgia rheumatica, arthritis
reumatska polimialgija, artritis
polymyalgia rheumatica, myositisd, arthritis, muscular weaknessd
reumatska polimialgija,miozitisd, artritis, mišićna slabost
polymyositisd
polimiozitis
polyneuropathy
polineuropatija
Polyolefin, PVC non-DEHP, or EVA intravenous tubing with a sterile, non-pyrogenic, low protein-binding 0.2 micrometre in-line filter.
Poliolefinska intravenska cjevčica, PVC intravenska cjevčica bez dietilheksilftalata ili EVA intravenska cjevčica koja sadrži sterilni, nepirogeni filter od 0,2 mikrometra niskog afiniteta za vezanje proteina.
Polyolefin, PVC non-DEHP, or EVA intravenous tubing with a sterile, non-pyrogenic, low protein-binding 0.2 micrometre in-line filter;
Poliolefinska intravenska cjevčica, PVC intravenska cjevčica bez dietilheksilftalata ili EVA intravenska cjevčica koja sadrži sterilni, ne-pirogeni filter od 0,2 mikrometra niskog afiniteta za vezanje proteina;
Polyoma (BK)) have been observed.
Polyoma (BK) infekcije).
Polyomavirus
Polioma virus
Polyoxyethylene fatty acids
Kolagen hidrolizat Soli
Polyoxyethylene oleic alcohol Potassium chloride,
Polioksietilen oleilni alkohol
Polyploidy (numerical chromosome aberrations) was observed in human peripheral blood lymphocytes in vitro, both in the presence and absence of metabolic activation.
U humanim limfocitima u perifernoj krvi opažena je poliploidija (numeričke kromosomske aberacije) in vitro, i u prisutnosti i u odsutnosti metaboličke aktivacije.
Polypropylene (PP) vials containing 50 ml, 250 ml and 500 ml of solvent closed with type I polymeric elastomer closures and aluminium caps.
Bočice od polipropilena (PP) koje sadrže 50 ml, 250 ml i 500 ml otapala zatvorene čepovima od polimerskog elastomera tipa I i aluminijskim poklopcima.
Polypropylene bottle Bottle of 10 or 25 doses
Polipropilenska boca Boca s 10 ili 25 doza
Polypropylene bottle containing 3 ml with a polyethylene dropper and a tamper proof child resistant closure.
Polipropilenska bočica od 3 ml, s polietilenskom kapaljkom i sigurnosnim zatvaračem za zaštitu od djece.
Polypropylene bottle with a butyl elastomer closure and sealed with an aluminium cap.
Polipropilenska boca s butilnim elastomernim zatvaračem i zatvorena aluminijskim čepom.
polypropylene polyethylene lined PVC polyurethane
polipropilena polietilenom obloženog PVC-a poliuretana
Polypropylene tablet containers with tamper evident polyethylene closure containing 250 & 500 film- coated tablets per tablet container.
Polipropilenski spremnici za tablete s polietilenskim zatvaračem s evidencijom otvaranja sadrže 250 i 500 filmom obloženih tableta po spremniku za tablete.
Polypropylene tablet containers with tamper evident polyethylene closure containing 250 & 500 tablets per tablet container.
Svaka filmom obložena tableta sadrži 228 mg bezvodne laktoze po tableti.
Polypropylene vial of 100, 250 or 500 ml with a chlorobutyl rubber stopper and an aluminium cap.
Propilenska bočica od 100, 250, ili 500 ml s klorbutilnim gumenim čepom i aluminijskom kapicom.
polyps)*
ciste i polipe)
Polysorbate 20
polisorbat 20
Polysorbate 20 (E 432) Sodium chloride Water for injections
histidin polisorbat 20 (E 432) natrijev klorid voda za injekcije
Polysorbate 80 (E 433), polyvinyl alcohol (E 1203), titanium dioxide (E 171), talc (E 553b), soya lecithin (E 322), xanthan gum (E 415).
Polisorbat 80 (E 433), poli)vinilni alkohol) (E 1203), titanijev dioksid (E 171), talk (E 553b), sojin lecitin (E 322), ksantanska guma (E 415).
Polysorbate 80 (E433) and phosal 50 PG (phosphatidylcholine, propylene glycol, mono-and diglycerides, ethanol, soya fatty acids, and ascorbyl palmitate).
Polisorbat 80 (E433) i fosal 50 PG(fosfatidilkolin, propilenglikol, mono- i digliceridi, etanol, masne kiseline soje i askorbilpalmitat).
Polysorbate 80 (Tween 80) 17 l
Polisorbat 80 (Tween 80) 17 l
Polysorbate 80 1.175 milligrams
Polisorbat 80 1,175 miligrama
polysorbate 80 1.175 milligrams per 0.5 ml sorbitan trioleate 1.175 milligrams per 0.5 ml
polisorbat 80 1,175 miligrama na 0,5 ml sorbitan trioleat 1,175 miligrama na 0,5 ml
polysorbate 80 1.175 milligrams per 0.5 ml sorbitan trioleate 1.175 milligrams per 0.5 ml For a full list of excipients see section 6.1.
polisorbat 80 1,175 miligrama na 0,5 ml sorbitantrioleat 1,175 miligrama na 0,5 ml Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams
polisorbat 80 1,175 miligrama sorbitantrioleat 1,175 miligrama
Polysorbate 80 Ethanol (anhydrous)
Polisorbat 80 Etanol (bezvodni)
Polysorbate 80 Ethanol anhydrous Citric acid
polisorbat 80 etanol bezvodni citratna kiselina
Polysorbate 80 Ethanol anhydrous Citric acid anhydrous
polisorbat 80 etanol bezvodni citratna kiselina
Polysorbate 80 Ethanol anhydrous Citric acid anhydrous
polisorbat 80 etanol, bezvodni citratna kiselina, bezvodna
Polysorbate 80 Mannitol Sucrose Methionine
Polisorbat 80 Manitol Saharoza Metionin
Polysorbate 80 Potassium Chloride
Polisorbat 80 Kalij klorid
Polysorbate 80 Simethicone Sodium chloride Potassium chloride
Polisorbat 80 Simetikon Natrijev klorid Kalijev klorid
polysorbate 80 sunset yellow FCF (E110)
“sunset yellow FCF ” (E110)
Polysorbate 80 Water for injections
Polisorbat 80 Voda za injekcije
Polyuria and polydipsia may be observed.
Mogu se pojaviti poliurija, polidipsija.
Polyuria Urine flow decreased
manjen protok mokraće
Polyuria Urine flow decreased
manjeno izlučivanje mokraće
Polyuria Urine flow decreased
polakizurija
Polyuria Urine flow decreased
retencija mokraće6 poliurija smanjen protok mokraće
Polyuria, haematuria, nocturia
poliurija, hematurija, nokturija
polyvalent ions)
polivalentnim ionima)
Polyvinyl alcohol
poli(vinilni alkohol)
Polyvinyl alcohol (E1203), macrogol 3350 (E1521), titanium dioxide (E171), talc (E553B), iron oxide red (E172).
Polivinilni alkohol (E1203), makrogol 3350 (E1521), titanijev dioksid (E171), talk (E553B), crveni željezov oksid (E172).
Polyvinyl alcohol (E1203), macrogol 3350 (E1521), titanium dioxide (E171), talc (E553B), sunset yellow FCF (E110).
Polivinilni alkohol (E1203), makrogol 3350 (E1521), titanijev dioksid (E171), talk (E553B), sunset yellow FCF (E110).
Polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol (E1521), talc (E553b), indigo carmine aluminium lake (E132), iron oxide yellow (E172).
Polivinilni alkohol (E1203), titanijev dioksid (E171), polietilen glikol (E1521), talk (E553b), boja indigo carmine aluminium lake (E132), željezov oksid žuti (E172)
Polyvinyl alcohol (partially hydrolysed) Titanium dioxide (E 171)
Polivinilni alkohol (djelomično hidroliziran) Titanijev dioksid (E 171)
Polyvinyl alcohol (partially hydrolysed), titanium dioxide (E 171) macrogol 3000,talc
Polivinilni alkohol (djelomično hidroliziran), titanijev dioksid (E 171), makrogol 3000, talk
Polyvinyl alcohol Titanium dioxide (E171) Macrogol
polivinilni alkohol titanijev dioksid (E171) makrogol
Polyvinyl alcohol Titanium dioxide Macrogol
poli(vinilni) alkohol titanijev dioksid makrogol
Polyvinyl alcohol Titanium dioxide Macrogol 3350 Talc
poli(vinilni alkohol) titanijev dioksid makrogol 3350
Polyvinyl alcohol – part. hydrolyzed Macrogol 4000
polivinilni alkohol – djelomično hidroliziran makrogol 4000
Polyvinyl alcohol – part. hydrolyzed Macrogol 4000
polivinilni alkohol, djelomično hidroliziran makrogol 4000
Polyvinyl alcohol, partly hydrolysed Talc
polivinilni alkohol, djelomično hidroliziran talk
Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, indigo carmine aluminium lake (E132).
Polivinilni alkohol, titanijev dioksid, makrogol 3350, talk, boja indigo carmine aluminium lake (E132)
Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, iron oxide black (E172).
Poli(vinilni alkohol), titanijev dioksid, makrogol 3350, talk, ţeljezov oksid, crni (E172)
Polyvinyl chloride (PVC) blisters with aluminium foil backing in a carton containing 30, 60, 90 film- coated tablets and multipacks containing 180 (2 packs of 90) film-coated tablets.
Polivinil klorid (PVC) blisteri prekriveni aluminijskom folijom u kutiji sa 30, 60, 90 filmom obloženih tableta i višestruka pakiranja koja sadrže 180 (2 pakiranja od 90) filmom obloženih tableta.
Polyvinyl chloride (PVC) laminated with polychloro-trifluoroethylene (PCTFE)/aluminium push-through layer.
Polivinilklorid (PVC) obložen poliklorotrifluoroetilen (PCTFE)/aluminijskim protisnim slojem.
Polyvinyl chloride (PVC)/aluminium foil push through blister units.
Blisteri od polivinilklorid (PVC)/aluminijske folije.
Polyvinyl chloride (PVC)/aluminium foil push-through blister units (blister card of 10 tablets).
Blisteri od polivinilklorid (PVC)/aluminijske folije (blister s 10 tableta).
Polyvinyl chloride (PVC)/aluminium foil push-through blister units (blister card of 7 tablets).
Blisteri od polivinilklorid (PVC)/aluminijske folije (blister sa 7 tableta).
Polyvinylchloride (PVC) / Polychlorotrifluoroethylene (PCTFE) / Aluminium foil blisters containing 7 hard capsules.
Blisteri od polivinilklorid (PVC) / poliklorotrifluoroetilen (PCTFE) / aluminijske folije koji sadrže 7 tvrdih kapsula.
Polyvinylchloride bag containing 200 ml, 400 ml or 800 ml in individual over-pouch.
Vrećica od polivinilklorida koja sadrži 200 ml, 400 ml ili 800 ml u pojedinačnim paketićima.
Pom+LD-Dex (N=302)
Pom + LD-Dex (N=302)
Pomalidomide also inhibits angiogenesis by blocking the migration and adhesion of endothelial cells.
Također inhibira angiogenezu blokadom migracije i adhezije endotelnih stanica.
Pomalidomide crossed the placenta and was detected in foetal blood following administration to pregnant rabbits.
Pomalidomid je prelazio placentu i bio je detektiran u fetalnoj krvni nakon primjene skotnim ženkama kunića.
Pomalidomide dose modification instructions
Upute za prilagodbu doze pomalidomida
Pomalidomide dose modification or interruption
Prilagodba doze pomalidomida ili prekid liječenja
Pomalidomide doses as high as 50 mg as a single dose in healthy volunteers, and 10 mg as once-daily multiple doses in multiple myeloma patients have been studied without reported serious adverse events related to overdose.
U zdravih dobrovoljaca ispitane su doze pomalidomida od čak 50 mg kao jednokratna doza, a u bolesnika s multiplim mijelomom doze od 10 mg kao višekratne doze primjenjivane jedanput na dan, bez zabilježenih ozbiljnih nuspojava povezanih s predoziranjem.
Pomalidomide has a mean total body clearance (CL/F) of approximately 7-10 L/hr.
Ukupni prosječni klirens pomalidomida iz organizma (CL/F) približno 7-10 l/h.
Pomalidomide interruption or discontinuation should be considered for Grade 2-3 skin rash.
U slučaju osipa na koži 2. do 3. stupnja treba razmotriti privremeni prekid ili ukidanje primjene pomalidomida.
Pomalidomide is expected to be harmful to the unborn child, causing severe and life-threatening birth defects.
Očekuje se da će pomalidomid djelovati štetno na nerođenu djecu i uzrokovati teške i po život opasne prirođene malformacije.
Pomalidomide is present in human semen during treatment.
Pomalidomid je prisutan u ljudskom sjemenu tijekom liječenja.
Pomalidomide must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, and should not be resumed following discontinuation for these reactions.
Pomalidomid se mora trajno ukinuti u slučaju angioedema, osipa 4. stupnja, eksfolijativnog ili buloznog osipa, a s primjenom se ne smije ponovo započeti nakon što se jednom ukine zbog ovih reakcija.
Pomalidomide must be discontinued permanently for angioedema, Grade 4 rash, exfoliative or bullous rash.
Pomalidomid se mora trajno ukinuti u slučaju angioedema, osipa 4. stupnja, eksfolijativnog ili buloznog osipa.
Pomalidomide was removed by haemodialysis.
Pomalidomid se uklanja hemodijalizom.
Pomalidomide works in a number of ways in multiple myeloma, similarly to other immunomodulating agents such as lenalidomide and thalidomide: it blocks the development of tumour cells, prevents the growth of blood vessels within tumours and also stimulates some of the specialised cells of the immune system to attack the tumour cells.
Pomalidomid djeluje na brojne načine kod multipli mijeloma, slično kao i drugi imunomodulatorni agensi poput lenalidomida i talidomida: blokira razvoj tumorskih stanica, sprječava urastanje krvnih žila u tumore i također potiče neke od specijaliziranih stanica imunosnog sustava na napad na tumorske stanice.
Pompe disease belongs to the lysosomal storage disorders as it is caused by a deficiency of a naturally-occurring lysosomal hydrolase, acid α- glucosidase (GAA) that degrades lysosomal glycogen to glucose.
Pompeova bolest pripada skupini poremećaja pohrane lizosoma jer je uzrokuje nedostatak prirodne lizosomske hidrolaze, kisele α-glukozidaze (GAA), koja lizosomski glikogen razlaže u glukozu.
Pompe Registry
Registar oboljelih od Pompeove bolesti
pon
astav
ponge your child’s skin with cool (not cold) water
pužvom vlažite kožu djeteta vodom normalne temperature (ne hladnom)
pontaneous abortion. azoospermia (lack of sperm production).
pontani pobačaj. azoospermija (smanjeno stvaranje spermija).
pontaneous bleeding
pontano krvarenje
pontaneous erection
pontana erekcija
pontaneous erection without sexual stimulation
pontana erekcija bez seksualne stimulacije
pontaneous reporting,
iz spontanih prijava,
POOLED
OBJEDINJENI PODACI
Pooled analyses of adverse event data from placebo controlled studies in Parkinson’s disease patients indicate that the concomitant administration of safinamide together with a broad category of commonly used medicinal products in this patient population (antihypertensive, beta-blockers cholesterol lowering, non-steroidal anti-inflammatory medicinal products, proton pump inhibitors, antidepressants, etc.) was not associated with an increased risk for adverse events.
Objedinjene analize podataka o štetnim događajima iz placebom kontroliranih ispitivanja bolesnika s Parkinsonovom bolešću ukazuju na to da istovremena primjena safinamida zajedno sa širokom kategorijom uobičajeno primjenjivanih lijekova u populaciji tih bolesnika (antihipertenzivi, beta blokatori, lijekovi za snižavanje kolesterola, nesteroidni protuupalni lijekovi, inhibitori protonske pumpe, antidepresivi, itd.) nije povezana s povećanim rizikom za štetne događaje.
Pooled analyses of adverse reactions reported up to the cut-off date of the analysis for studies C2305 and C2402 are presented in Table 1.
Objedinjene analize nuspojava prijavljenih do isključnog datuma za analizu za ispitivanja C2305 i C2402 navedene su u Tablici 1.
Pooled C208 and C216 N = 785
Objedinjena C208 i C216 N = 785
Pooled Data
Zbirni podaci
Pooled data from the ECHO and THRIVE trials
Objedinjeni podaci iz ispitivanja ECHO i THRIVE
Pooled data from the pivotal RCC trial (VEG105192, n=290), extension study (VEG107769, n=71), the supportive Phase II trial (VEG102616, n=225) and the randomised, open-label, parallel group Phase III non- inferiority study (VEG108844, n=557) was evaluated in the overall evaluation of safety and tolerability of pazopanib (total n=1149) in subjects with RCC (see section 5.1).
Združeni podaci iz ključnog RCC ispitivanja (VEG105192, n=290), produžetka ispitivanja (VEG107769, n=71) i pratećeg ispitivanja faze II (VEG102616, n=225), kao i randomiziranog, otvorenog ispitivanja neinferiornosti faze III s paralelnim skupinama (VEG108844, n=557) procijenjeni su u sveukupnoj procjeni sigurnosti i podnošljivosti pazopaniba (ukupno n=1149) u ispitanika s RCC (vidjeti dio 5.1).
Pooled data from the pivotal STS trial (VEG110727, n=369) and the supportive Phase II trial (VEG20002, n=142) was evaluated in the overall evaluation of safety and tolerability of pazopanib (total safety population n=382) in subjects with STS (see section 5.1).
Združeni podaci iz glavnog STS ispitivanja (VEG110727, n=369) i pratećeg ispitivanja faze II (VEG20002, n=142) procijenjeni su u sveukupnoj procjeni sigurnosti i podnošljivosti pazopaniba (sveukupna populacija za procjenu sigurnosti n=382) u ispitanika s STS-om (vidjeti dio 5.1).
Pooled data from these studies demonstrated a significant advantage for Ibandronate 50 mg p.o. over placebo in the reduction in SREs measured by the SMPR (p=0.041).
Podaci prikupljeni tijekom ovog ispitivanja pokazali su znatnu prednost ibandronata 50 mg peroralno u odnosu na placebo u pogledu smanjivanja SRE, mjereno SMPR-om (p=0,041).
Pooled DUET Studies
Udružena DUET ispitivanja
Pooled Efficacy Analysis
Objedinjena analiza djelotvornosti
Pooled efficacy analysis over 6 months’ treatment demonstrated that the rate of COPD exacerbations was statistically significantly lower than the placebo rate.
Objedinjena analiza djelotvornosti tijekom 6 mjeseci liječenja pokazala je značajno nižu stopu egzacerbacija KOPB-a nego u placebo grupi.
Pooled phase 3 studies
Objedinjena ispitivanja faze 3
Pooled Phase III studies
Objedinjene studije faze III
Pooled post-hoc analyses of clinical studies of ESAs have been perfomed in CRF patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients).
U bolesnika s kroničnim zatajenjem bubrega (u onih na dijalizi i onih koji nisu na dijalizi, koji imaju ili nemaju dijabetes) provedene su post-hoc analize objedinjenih podataka iz kliničkih ispitivanja lijekova koji stimuliraju eritropoezu.
Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients).
Provedena je post-hoc analiza objedinjenih podataka iz kliničkih ispitivanja LSE-a u bolesnika s kroničnim zatajenjem bubrega (koji su na dijalizi, koji nisu na dijalizi, kod dijabetičara i ne- dijabetičara).
Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients).
U bolesnika s kroničnim zatajenjem bubrega (u onih na dijalizi i onih koji nisu na dijalizi, koji imaju ili nemaju dijabetes) provedene su post-hoc analize objedinjenih podataka iz kliničkih ispitivanja lijekova za stimulaciju eritropoeze.
Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients).
U bolesnika s kroničnim zatajenjem bubrega (u onih na dijalizi i onih koji nisu na dijalizi, koji imaju ili nemaju šećernu bolest) provedene su post-hoc analize objedinjenih podataka iz kliničkih ispitivanja ESA.
Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients).
U bolesnika s kroničnim zatajenjem bubrega (u onih na dijalizi i onih koji nisu na dijalizi, koji imaju ili nemaju šećernu bolest) provedene su post-hoc analize objedinjenih podataka iz kliničkih ispitivanja lijekova za stimulaciju eritropoeze.
Pooled post-hoc analyses of clinical studies with ESAs have been performed in CRF patients (on dialysis, not on dialysis, with or without diabetes).
U bolesnika s kroničnim zatajenjem bubrega (u onih na dijalizi i onih koji nisu na dijalizi, koji imaju ili nemaju dijabetes) provedene su post-hoc analize objedinjenih podataka iz kliničkih ispitivanja lijekova za stimulaciju eritropoeze.
Pooled results across the 3 treatment levels
Objedinjeni rezultati sve 3 razine liječenja
Pooled Stages 1 & 2
Objedinjeni dijelovi 1 & 2
Pooled studies (046, 047, 074)
Objedinjena ispitivanja (046, 047, 074)
Pooled studies consisted of 046 (Europe / Australia), 047 (North America [NA]) and 074 (Europe / NA).
Objedinjeni rezultati ispitivanja uključivali su rezultate ispitivanja 046 (Europa/Australija), 047 (Sjeverna Amerika) i 074 (Europa/Sjeverna Amerika).
Pooled studies consisted of studies 046 (Europe / Australia), 047 (North America [NA]) and 074 (Europe / NA).
Objedinjeni rezultati ispitivanja uključivali su rezultate ispitivanja 046 (Europa/Australija), 047 (Sjeverna Amerika) i 074 (Europa/Sjeverna Amerika).
Pooled treatment outcomes at 48 and 96 weeks are shown in Table 3.
Objedinjeni ishodi liječenja u 48. i 96. tjednu prikazani su u Tablici 3.
Pooled treatment outcomes at 48 and 96 weeks are shown in Table 4.
Objedinjeni ishodi liječenja u 48 i 96 tjedana prikazani su u Tablici 4.
Pooled treatment outcomes at 48 weeks are shown in Table 3.
Objedinjeni ishodi liječenja u 48 tjedana prikazani su u Tablici 3.